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Epidemiologic studies have indicated that n-3 polyunsaturated fatty acids (PUFAs) 
supplementation may reduce the incidence of breast cancer, also in vivo and in vitro studies 
have shown that n-3 PUFAs have an inhibitory effect on breast cancer cells. One important n-
3 PUFA are eiocosapentaenoic acid (EPA), which are metabolized to five regioisomeric 
epoxyeicosatetraenoic acids (epoxy-EPAs) by the cytochromes P450 system. Further, these 
epoxides are metabolized by epoxide hydrolase (EH), which can be inhibited by N, N`-
dicyclohexylurea (DCU), an epoxide hydrolase inhibitor (EHI). The effect of these five 
epoxy-EPAs and the combination of epoxy-EPAs and EHI on breast cancer cells is not 
known. 
 
In this study the effect of 8, 9-epoxy-EPA on the human estrogen responsive breast cancer 
cell line MCF-7 was tested.  MCF-7 cells were treated with 8, 9-epoxy-EPA, DCU and a 
combination of 8, 9-epoxy-EPA + DCU. Both the treatment with 8, 9-epoxy-EPA and the 
combination of 8, 9-epoxy-EPA + DCU inhibited the growth of MCF-7 cells in the presence 
of FBS. Treatment with 8, 9-epoxy-EPA in the absence of FBS did not result in a change in 
cell viability, which indicates that the growth inhibition on MCF-7 cells by 8, 9-epoxy-EPA 
requires an additional proliferative stimulus. To examine the effects of 8, 9-epoxy-EPA on 
MCF-7 cell growth flow cytometry was used to monitor cell cycle progression. Cells treated 
with 8, 9-epoxy-EPA and the combination of 8, 9-epoxy-EPA + DCU for 16 and 24 hours 
were found to be arrested in G0/G1-phase, and did not progress through the cell cycle at the 
same rate as control cells. 8, 9-epoxy-EPA treatment for 24 hours also resulted in a 
corresponding decrease in G2/M-phase. The adding of DCU did not enhance the effect of the 
8, 9-epoxy-EPA treatment on cell cycle progression significantly. Treatment in the absence of 
FBS showed no alteration in the progression of the cell cycle. The growth inhibition effect on 
MCF-7 cells of 8, 9-epoxy-EPA was further studied by examining changes in expression of 
different cell cycle regulatory proteins. The protein levels were found to be unaltered after 8, 
9-epoxy-EPA treatment. The growth inhibition effect may be due to increased cell apoptosis 
as an alternative to decreased proliferation in MCF-7 cells. This possibility should be 



































AA     Arachidonic acid 
BCA-assay    Bicinchoninic-assay 
CDK     Cyclin-dependent protein kinase 
COX     Cyclooxygenase 
CYP-450    Cytochromes P450 system 
DCU     N, N`-dicyclohexylurea 
DHA     Docosahexaenoic acid 
DHET     Dihydroxyeicosatrienoic acids 
DMEM    Dulbecco`s modified eagle medium 
DMSO    Dimethyl sulfoxide 
EET     Epxoyeicosatrienoic acid   
EH     Epoxide hydrolase 
EHI     Epoxide hydrolase inhibitor 
EPA     Eicosapentaenoic acid 
8, 9-epoxy-EPA   8, 9-epoxy-eicosatetraenoic acid 
FBS     Fetal bovine serum 
HIF-1     Hypoxia-inducible factor-1 
LA     Linoleic acid 
LAF-bench    Laminar Air Flow bench 
LOX     Lipooxygenase  
MTT     Thiazolyl blue tetrazolium bromide 
NFκB     Nuclear factor κB 
PG     Prostaglandin 
PUFA     Polyunsaturated fatty acid 





































In 2005 7.6 million people died of cancer, which accounts for 13% of the total deaths 
worldwide. The deaths caused by cancer are expected to continue to rise, and it is estimated 
that in 2015 nine million people will die of cancer. In Norway, there were 24 488 incident 
cases of cancer in 2006. Breast cancer is one of the major cancer forms among women, and 
each year 502,000 people die of breast cancer worldwide. In 2006, there were 2673 new cases 
of breast cancer in Norway. Factors that are associated with a higher risk of cancer are 
geographic and environmental factors, age, heredity and clinical conditions. In breast cancer 
there are also other risk factors like gender, hormonal relations (early menstruation and late 
menopause), atypical hyperplasia, long-lasting postmenopausal estrogen therapy, previous 
breast cancer, overweight and alcohol [1-3]. 
 
In cancer, cells do not respond to normal growth control because of changes in the genes that 
control the cell growth and repair. Changes in these genes can be caused by physical (UV, 
ionizing radiation), chemical (asbestos, tobacco smoke) or biological (infection by virus or 
bacteria) carcinogens. There are often mutations in oncogenes and tumor suppressor genes. 
Oncogenes are derived by mutations in protooncogenes, and promote cell growth in cancer 
cells in the absence of normal growth-promoting signals. Tumor supressor genes encode 
proteins that normally inhibit cell division [2, 3]. 
 
A neoplasm, also called a tumor, is an abnormal mass of tissue consisting of cells that are 
genetically altered, and do not respond to normal growth regulation. A tumor is completely 
depended on the host for nutrition and blood supply, and sometimes endocrine support. 
Tumors can be classified as benign or malign, based on its properties. A malign tumor have 
uncontrolled cell division, can invade adjacent tissues and spread to other parts of the body 
via lymph and blood (metastasis). Cancer cells can be well-differentiated, but are often less 
differentiated than normal cells. Differentiation is a process where cells undergo a change to 
perform a specific function. Benign tumors do not invade or infiltrate the surrounding normal 




Tumors consist of two basic components called the parenchyma and the stroma. The 
parenchyma is made up of neoplastic cells, which determines the biologic behavior of the 
tumor. The stroma consists of connective tissue and blood vessels, which carries blood supply 
and provides support for growth of the tumor. The growth of the tumor is determined by cell 
kinetics (the rate of cell division and the rate of cells lost), blood supply, and some also 
depend on hormones. Breast cancer tumors can be regulated by steroid hormones (estrogens, 
progesterones, and androgens), growth factors, insulin and insulin-like growth factors (IGF-1) 
[1, 3]. 
1.1.1 Angiogenesis 
Angiogenesis is the process by which new capillaries are formed in a tumor. A tumor that 
grows beyond 1-2 mm in diameters cannot enlarge unless formation of new capillaries, 
because 1-2 mm is the maximal distance oxygen and nutrients can diffuse from blood vessels.  
Tumor cells can produce and induce tumor-associated angiogenic factors, the two most 
important being vascular endothelial growth factor (VEGF) and basic fibroblast growth 
factor. When tumors are exposed to hypoxia, angiogenesis are induced by the release 
hypoxia-inducible factor-1 (HIF-1), which controls the transcription of VEGF. Since 
angiogenesis is important for the growth of the tumor it is a potential target for anticancer 
treatment [3]. 
 
1.2 Cell cycle 
The eukaryotic cell cycle consists of four phases, called G1-, S-, G2- and M-phase as shown 
in figure 1.1. In the S-phase, synthesis-phase, the DNA-synthesis produces to copies of the 
DNA to both daughter cells. Between S-phase and cell division, G2–phase, RNA and proteins 
are synthesized. The cell divides into to genetically identical daughter cells in the M-phase, 
the mitotic phase. This phase consists of division of the cell nucleus, mitosis, and cytoplasm 
to produce two daughter cells, cytokinesis. After the cell division the daughter cells can enter 
G1-phase, where RNA and proteins are synthesized, and continue to division or a quiescent 
phase, G0 [6, 7]. 
1.2.1 Regulation of the cell cycle 
The control of when a cell divide, differentiate or become permanently quiescent is important 
for the organism. The cell cycle is regulated by a family of protein kinases, which are 
enzymes that phosphorylate specific proteins by catalyzing the transfer of a phosphate group 
from ATP. These kinases consist of a regulatory subunit, cyclin, and a catalytic subunit, 
cyclin-dependent protein kinase (CDK). When cyclin bindes to CDK and forms the cyclin-
CDK complex, CDK becomes activated. There are four mechanisms that modulate the 
activity of specific CDKs. These mechanisms involve phosphorylation/dephosphorylation of 
CDKs, proteolytic breakdown of mitotic cyclins, regulation of the rate of synthesis of cyclin 
or CDK and the binding of specific protein inhibitors (for example p21) that inactivate CDK. 
During the cell cycle, different cyclins and CDKs form cyclin-CDK complexes. The cyclin D 
family is associated with the progression of cells from G0-phase to G1-phase, where cyclin D 
forms a complex with CDK4. When the cells approaches S-phase cyclin E bind to CDK2, and 
in the end of the S-phase when cyclin E is degraded cyclin A bind. During G2 phase cyclin B 




Figure 1.1: The cell cycle 
 
1.3 Flow cytometry 
To determine the proportion of cells in each of the cell cycle phases flow cytometry 
techniques can be used. Cells are fixed and labeled with a DNA-binding fluorescent probe 
(for example propidium iodide). The cell suspension passes through a narrow chamber as a 
single droplet with the size of one single cell. Lasers excite fluorescent dyes by sending out 
13 
 
monochromatic light of specific wavelengths, which are deflected or reflected depending on 
the size and density of the cell. The light emission from the dye is assayed by photon 
detectors, and computer software can analyze the data. The DNA-binding fluorescent probe 
will bind to the DNA, and the fluorescence is proportional with the amount of DNA in the 
cell. Cells in G0- and G1-phase should have the same amount of DNA, and when they are in 
G2-phase the amount of DNA is doubled. If cells have a DNA concentration between G1- and 
G2-phase they are assumed to be in S-phase. A typical frequency distribution of the DNA will 
show two peaks, the first one representing cells in G0/G1-phase and the other representing 
cells in G2/M-phase as shown in figure 1.2. Cells in S-phase are represented by the plateau 
between the peaks [5].  
 
 
Figure 1.2: Flow-cytometric analysis 
 
1.4 Apoptosis 
Some of the same proteins that regulate the cell cycle also regulate the cells` time of death, 
the process of programmed cell death also called apoptosis. Apoptosis is important in many 
biological processes, and the result of an avoided apoptosis can be cancer. Apoptosis are 
triggered by cell death signals (for example tumor necrosis factor) or DNA damage (for 
example caused by ultraviolet light or radiation). These external signals and internal changes 
activate caspases, which are enzymes that mediate apoptosis. During the apoptosis the cells` 
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chromatin condenses and the cytoplasm shrinks. After the nucleus becomes fragmented and 
its DNA digested, the cell extends to numerous blebs. The small pieces of the cells, the 
apoptotic bodies, are ingested by phagocytic cells [5, 7]. 
 
1.5 Omega-3 and omega-6 fatty acids 
Fatty acids are hydrocarbon chains that are substituted with a carboxyl group at one end. The 
carbon atoms are connected by either single or double bonds. Saturated fatty acids have only 
single bonds connecting the carbon atoms, and are fully saturated with hydrogen. 
Monounsaturated and polyunsaturated fatty acids (PUFAs) have one or more double bonds 
connecting the carbon atoms [8].  
 
The omega-3 (n-3) and omega-6 (n-6) PUFAs are essential fatty acids, which mean that 
mammals cannot synthesize the n-3 and the n-6 double bond. Essential fatty acids must be 
consumed through diet, although short chain PUFAs can be converted to longer chain PUFAs. 
The n-6 fatty acid linoleic acid (LA, 18:2), which is found mostly in vegetable oils, can be 
converted to arachidonic acid (AA, 20:4). AA is found in meat, eggs and dairy products. In 
the body AA is found in phospholipids in cell membranes, and it is the precursor of 
eicosanoids. The n-3 fatty acid α-linoleic acid (ALA, 18:3) can be converted to 
eicosapentaenoic acid (EPA, 20:5) and docosahexaenoic acid (DHA, 22:6). EPA and DHA 










1.6 Metabolism of n-3 and n-6 fatty acids 
AA, an n-6 fatty acid, can be metabolized by three major systems; cyclooxygenases (COX), 
lipoxygenases (LOX) and the cytochromes P450 system (CYP-450). COX oxygenates AA to 
prostaglandins (PGs), thromboxanes and prostacyclin, and the LOX system oxygenates AA to 
leukotrienes, hydroxyeicosatetraenoic acids (HETEs) and lipoxins. The CYP-450 system 
oxidizes AA to hydroxyl and epoxy fatty acids.  EPA and DHA, n-3 fatty acids, can be 
metabolized by human CYP-450 families 1, 2 and 3 to epoxides, and also competitively 
inhibit the metabolism of AA by the CYP-450 system [9]. EPA can be oxidized at any of the 
five double bonds in the fatty acid structure to five regioisomeric epoxyeicosatetraenoic acids 
(5,6-, 8,9-, 11,12-, 14,15-, and 17,18-epoxy-EPAs) and hydroxylated to 19- and 20-OH-EPA 
by the CYP-450 system [9]. 
 
Further, AA-derived epoxides (EETs) are rapidly metabolized by hydration of the epoxide 
group to diols catalyzed by cytosolic epoxide hydrolase, or to shorter fatty acid epoxide 
chains by β-oxidation [10]. The conversion of EETs to the corresponding 
dihydroxyeicosatrienoic acids (DHETs) by epoxide hydrolase (EH), which is the main 
metabolic pathway, is inhibited by an epoxide hydrolase inhibitor (EHI) [10, 11], which 
stabilize the epoxide. The addition of N, N`-dicyclohexylurea (DCU), which is an EHI, results 
in an accumulation of EET in cells [10]. EPA-derived epoxides are also further metabolized 
by hydration of the epoxides to diols. This step is also mediated by epoxide hydrolase. The 
influence of inhibition of epoxide hydrolase on the amount and effect of EPA-derived 
epoxides is not known.  
 
1.7 The effect of omega-3 fatty acids on cancer cells 
The influence of dietary fat in breast cancer is not well understood, although epidemiologic 
data have indicated that n-3 fatty acid supplementation may reduce the incidence of breast 
cancer [12, 13]. However, it must be said that there are also studies that show no association 
between fish consumption and breast cancer [14, 15]. Thus, the precise details of dietary 
associations probably will come from findings in laboratory studies. Animal experiments have 
shown that n-3 PUFA have an inhibitory effect on breast cancer cells [16, 17] and other 
cancer cells [18]. In vitro experiments on breast cancer cells have indicated that n-3 fatty 
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acids inhibit proliferation [19-23]. This suggests that n-3 fatty acids may have value in 
nutritional therapy as a part of anti-cancer treatment regimen.  
 
1.8 Mechanisms of the effect on cancer cell growth of n-3 and n-6 fatty acids 
The n-3 fatty acids have been shown to inhibit the growth of cancer cells [19-22], while n-6 
fatty acids have been shown to stimulate the growth of cancer cells [24]. Various mechanisms 
have been proposed to explain the effect of n-3 fatty acids and n-6 fatty acids on cancer cell 
growth. One proposed mechanism is that n-3 fatty acids may lower the risk of cancer through 
reducing the production of AA-derived eicosanoids. AA-derived and n-3 fatty acids-derived 
eicosanoids have different effects on cancer cells. AA-derived eicosanoids like PGE2 have 
been found in higher concentrations in cancer cells compared to normal cells [25],  and have 
been shown to have proliferative effects on cancer cells [26]. While PGE3 produced from n-3 
fatty acids have been found to inhibit proliferation of cancer cells [27]. Proliferation is the cell 
reproduction process. As mentioned PUFAs are metabolized to prostaglandins and 
thromboxanes by COX-enzymes. n-3 Fatty acids may also decrease PGE3 production by 
decreasing the expression of COX and transcription nuclear factor κB (NFκB) [28]. Thus, n-3 
fatty acids can reduce the proliferative effect of AA-derived eicosanoids on cancer cells by 
mechanisms involving decreased PGE3 production by COX downregulation.  
 
The potential use of epoxides formed by the action of CYPs on n-3 PUFA has not been 
explored. In previous studies from this laboratory it has been found that an epoxide of the n-3 
PUFA EPA inhibited cell growth by decreasing proliferation. Thus, evidence has been 
produced that n-3 epoxides act in opposite fashion to n-6 PUFA epoxides (the EETs). EETs 
have been shown to inhibit the pronounced death of tumor cells (or apoptosis) and to 
stimulate proliferative cell growth.  
 
Nuclear factor κB is a transcription factor that regulates genes that control cell proliferation 
and cell survival. Apoptosis can be blocked by NF-κB, which means that the cells do not die 
at the appropriate time. However, there are additional mechanisms. EETs inhibit apoptotic 
pathway in cells, but the mechanism is not fully understood [29]. Breast cancer cells have 
been shown to express high levels of functional nuclear NF-κB/Rel activity [30], and the n-3 
fatty acids can decrease NF-κB activation [31]. Any involvement of CYP 450-derived 
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epoxides in effects on apoptosis remains to be explored. However, our laboratory have 
previously found that increased apoptosis by epoxy-EPA is minimal in endothelial cells. 
Therefore, the present study focused on the effects on cell proliferation. 
 
In a recent report our laboratory have shown that n-3 derived eicosanoids inhibit angiogenesis 
[32]. Eicosanoids may also regulate the growth of new blood vessels, or angiogenesis. 
Angiogenesis is necessary for the cancer tumor to grow, and the inhibition of angiogenesis 
has been proposed to inhibit the cancer tumor growth. It has been suggested that PGE2 can 
promote tumor angiogenesis [33]. Thus, treatment of human umbilical vein endothelial cells 
with n-3 EPA and PGE3 inhibited the stimulatory effect of growth factor on angiogenesis. In 
unpublished experiment a role for CYP-450 derived epoxides was also noted. Thus, evidence 
suggests that n-3 PUFA and their biotransformation products may exert multiple effects on 
tumor cells and tumor genesis. Likely mechanisms include decreased proliferation, decreased 
angiogenesis and decreased metastasis (or tumor spread). The potential effects of CYP 450-
derived n-3 epoxides on the proliferation of breast cancer cells, that have not previously been 
evaluated, are the major focus of the present project. 
 
1.9 The MCF-7 breast cancer cell line 
To study the effect of 8, 9-epoxy-eicosapentaeonic acid (8, 9-epoxy-EPA) on human breast 
cancer cells the MCF-7 cell line was chosen as cellular model. The MCF-7 cell line is 
estrogen responsive and contains the estrogen receptor [34, 35]. The cell line has been widely 
studied and exhibits relatively slow growth characteristics. Both EPA and DHA have been 
shown to have inhibitory effects on MCF-7 cell proliferation [16, 21]. In experiments AA 
have had a stimulatory effect on MCF-7 cells, and 8, 9-EET have been shown to have the 
same effect on a variety of human carcinoma cell lines [36]. The effects of EPA-derived 
epoxides on MCF-7 cells have not been studied to this date and will be the focus of this work.  
 
1.10 The aim of the thesis 
The aim of this project was to test the effect of 8, 9-epoxy-eicosapentaenoic acid on MCF-7 
cells. Since the MCF-7 cell line is estrogen responsive, the influence of FBS on the effect of 
8, 9-epoxy-EPA treatment was tested. Also the effect of the combination of 8, 9-epoxy-EPA 
and DCU, an epoxide hydrolase inhibitor, was assessed. The effects of 8, 9-epoxy-EPA were 
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assessed by examining cell viability, cell cycle progression and expression of cell cycle 
regulatory proteins in MCF-7 cells. After an optimization of growth effects, seeding density 
and FBS concentration, on MCF-7 cells, the effect of 8, 9-epoxy-EPA on cell viability was 
evaluated using macroscopic assessments and by counting cells manually by Trypan blue 
assay. To evaluate the effects of 8, 9-epoxy-EPA on cell cycle progression flow cytometric 
evaluation was used. Changes in the expression of cell cycle regulatory proteins were 



















































2 MATERIALS AND METHODS 
2.1 Materials  
2.1.1 Chemicals 
Table 2.1: Chemicals 
CHEMICALS PRODUCER 
8, 9-epoxy-eicosapentaenoic acid Gift from Dr Sarah Cui  
Acrylamide/Bis, 40% (29:1) Amresco ( Solon, Ohio, USA) 
Ammonium persulphate Univar, Aiax Chemicals (Sydney, Australia) 
Aprotinin Sigma Chemical Company  
(St. Louis, MO, USA) 
BCA Protein Assay Reagent Pierce (Rockford, Illinois, USA) 
Blocking buffer Rockland (Gilbertsville, PA, USA) 
Bromophenol blue  Sigma Chemical Company  
(St. Louis, MO, USA) 
Dimethyl sulfoxide (DMSO) Sigma Chemical Company  
(St. Louis, MO, USA) 
Diploma skim milk powder Diploma (Australia) 
Dithiothreitol (DTT) Sigma Chemical Company  
(St. Louis, MO, USA) 
Dulbecco’s modified eagle medium 
(DMEM) 
Thermo Fisher Scientific  
(Waltham, MA, USA) 
Fetal bovine serum (FBS) Thermo Fisher Scientific  
(Waltham, MA, USA) 
Glycine Amresco (Solon, Ohio, USA) 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
USB corporation  
(Cleveland, OH, USA) 
Leupeptin Sigma Chemical Company  
(St. Louis, MO, USA) 
L-glutamine Thermo Fisher Scientific  




N,N`-dicyclohexylurea (DCU) Sigma Chemical Company  
(St. Louis, MO, USA) 
Nonidet P450 (Igepal) Sigma Chemical Company  
(St. Louis, MO, USA) 
Penicillin/Streptomycin  Thermo Fisher Scientific  
(Waltham, MA, USA) 
Phosphate-buffered saline (PBS) tablets Amresco (Solon, Ohio, USA) 
PMSF (phenyl methyl sulfonyl fluoride) Sigma Chemical Company  
(St. Louis, MO, USA) 
Ponceau Stain ICN biomedical (Solon, Ohio, U.S.A.) 
Prestained protein molecular weight marker Fermentas (Canada) 
Propidium iodide Chemical Company (St. Louis, MO, USA) 
Ribonuclease A (Rnase A)  Chemical Company (St. Louis, MO, USA) 
SDS (sodium dodecyl sulphate) A.G. scientific inc (San Diego, CA, USA) 
Sodium deoxycholate  Sigma Chemical Company  
(St. Louis, MO, USA)  
Sodium hydrogen carbonate (NaHCO3) Univar, APS Aiax, Finechem  
(Auburn, NSW, Australia) 
TEMED Amresco (Solon, Ohio, USA) 
Thiazolyl blue tetrazolium bromide (MTT) Chemical Company (St. Louis, MO, USA) 
Tris Amresco (Solon, Ohio, USA) 
Trypan blue stain Invitrogen (Mount Waverley, VIC, Australia)
Trypsin/EDTA Thermo Fisher Scientific  
(Waltham, MA, USA) 









2.1.2 Solutions for cell culture 
Table 2.2 
Plain media, 900 ml 
Dulbecco’s modified eagle medium 
(DMEM) 
9.87 g 
Sodium hydrogen carbonate  1.2 g 
HEPES 5.21 g 
Baxter sterile water Ad 900 ml 
 
Table 2.3 
Media with 10% FBS, 255 ml 
Plain media 220 ml 
10% FBS 25 ml 
1% L-glutamate 2.5 ml 
1% Pencillin/Streptomycin Antibiotic Mix 2.5 ml 
 
Table 2.4 
Media with 2% FBS, 260 ml 
Plain media 250 ml 
2% FBS 5 ml 
1% L-glutamate 2.5 ml 
1% Pencillin/Streptomycin Antibiotic Mix 2.5 ml 
 
Table 2.5 
Media without FBS, 225 ml 
Plain media 220 ml 
1% L-glutamate 2.5 ml 










Media with 10% FBS 3.78 ml 
20% FBS 1.08 ml 
10% DMSO 0.54 ml 
Table 2.7 
Phosphate-buffered saline (PBS), pH7.4 
Phosphate-buffered saline (PBS) tablets 1 tablet 
Baxter sterile water 100 ml 
 
2.1.3 Solutions for flow cytometry 
Table 2.8 
Incubation buffer, 10 ml 
PBS 9.8 ml 
Nonidet P450 (Igepal) 0.1 ml 
Rnase A 0.1 ml 
 
Table 2.9 
Propidium iodide, 2 mg/ml 
Propidium idodie 10 mg 
PBS 5 ml 
 
2.1.4 Buffers for western blotting 
Table 2.10 
5x Electrophoresis buffer, pH 8.3 
Tris 15.0 g 
Glycine 72.0 g 
SDS 5.0 g 







1x Electrophoresis buffer, pH 8.3 
Electrophoresis buffer 
5x Tris-glycine pH 8.3 stock 
100 ml 
Deionized water 400 ml 
 
Table 2.12 
Sample (reducing) buffer 
1 M Tris pH 6.8 stock 25.0 ml 
Glycerol 23.0 ml 
10% SDS 40.0 ml 
0.1% Bromophenol blue  2.0 ml 
Deionized water  90 ml 
0.5 M DTT 0.5 ml 
 
Table 2.13 
Transfer buffer, 2 L 
Tris 6.06 g 
Glycine 28.8 g 
Methanol  400.0 ml 
Deionized water Ad 2L 
 
Table 2.14 
10x TBS , 2 L 
Tris 121.0 g 
NaCl 233.8 g 
Adjust pH to 7.4 using concentrated HCl  










10x TBS  100 ml 
Deionized water 900 ml 
Tween-20 0.5 ml 
 
Table 2.16 
Blocking buffer with 5% milk, 100 ml 
Diploma skim milk 5.0 g 
1x TBS/Tween 100 ml 
 
2.1.5 Gels for western blotting 
Table 2.17 
12 % separating gel,  2x1.5 mm gel 
Deionized water 11.4 ml 
40% acrylamide/Bis 9 ml 
2.5 M TrisHCl pH 8.8 9 ml 
10% (w/v) SDS 150 ul 
Ammonium persulphate (0.1g/ml) 300 ul 
TEMED 32 ul 
 
Table 2.18 
5 % stacking gel, 2x1.5 mm gel 
Deionized water 9.8 ml 
40% Acrylamide/Bis 2 ml 
2.5 M TrisHCl pH 6.8 4 ml 
10% (w/v) SDS 160 ul 
Ammonium persulphate (0.1g/ml) 80 ul 







0.5 M Tris, pH 6.8  
Tris  6.0 g 
Adjust pH to 6.8 with concentrated HCl  
Deionized water  ad 100 ml 
 
Table 2.20 
1.5 M Tris, pH 8.8 stock 
Tris  18.15 g 
Adjust pH to 8.8 with concentrated HCl  





Allegra 6R Centrifuge Beckman 
Altra 20 soft Imaging system CKX41 Olympus 
Biorad GS-800 Calibrated Densitometer Biorad 
Coulter flow cytometer Beckman 
Email Air Handling Biological safety cabinet 
class II 
Email 
Eppendorf Centrifuge 5417 R Crown Scientific 
Odyssey LI-COR 
Olympus CKX41 Olympus 
Victor3 Wallac 1420 multilabel counter  Perkin Elmer 
 
 
2.2. Cells and cell culture 
2.2.1 Cell culture 
MCF-7 cells isolated from a 69 years old Caucasian female were used [34]. Cells were 
maintained in monolayer culture in T75 flasks at 37oC in DMEM containing 100 units/ml 
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penicillin, 100 µg/ml streptomycin, 1% L-glutamine and 10% fetal bovine serum (FBS) in an 
atmosphere of 95% air and 5% CO2. All cell culture work was carried out on an aseptic LAF-
bench, and all equipment used in direct contact with cells was sterilized or autoclaved. 
2.2.2 Passaging MCF-7 cells  
Cells were passaged when they were 90% confluent, about every fourth day.  Media was 
removed by aspiration, and 10 ml of PBS were added to wash the media from the cells. To 
detach cells 2 ml of trypsin was added and cells were incubated at 37oC for 5 minutes. The 
T75 flask was tapped gently against the palm to detach cells, and cells were checked to be 
detached under the microscope. Cells were transferred to a centrifuge tube by adding 10 ml 
DMEM, and centrifuged at 1250 rpm (Allegra 6R Centrifuge, Beckman) for 5 minutes. The 
supernatant was removed, and the tube was “flipped” to separate cells. Cells were 
resuspended in 10 ml of DMEM. After the resuspension half of the cell stock was transferred 
into a T75 flask containing 25 ml DMEM. Media, PBS and trypsin was heated to 37oC before 
addition.  
2.2.3 Thawing MCF-cells 
10 ml of DMEM containing 10% FBS was added in a centrifuge tube. Cells kept in cryotubes 
in liquid nitrogen were quickly warmed in a water bath at 37oC. DMEM containing 10% FBS 
was added, and cells were transferred to a centrifuge tube. Cells were centrifuged at 1250 rpm 
(Allegra 6R Centrifuge, Beckman) for 5 minutes, and the supernatant was removed by 
aspiration. The centrifuge tube was flipped to separate cells, and cells were resuspended in10 
ml of DMEM. The cell stock was transferred into a T75 flask containing 25 ml DMEM.  
 
2.3 Treatment with 8, 9-epoxy-EPA 
In the experiments MCF-7 cells were treated with 10 µM 8, 9-epoxy-EPA dissolved in 
DMSO, and cells added DMSO was used as control cells. Cells were also treated with a 
mixture of 10 µM 8, 9-epoxy-EPA + 10 µM DCU, and cells treated with 10 µM DCU was 




2.4 MCF-7 cell count 
To prepare a cell suspension with the appropriate cell concentration for seeding, cells were 
counted using a Hemacytometer. A hemacytometer is a graduated counting chamber for 
determining the concentration of cells in a suspension. Approximately 10 µl of the cell 
suspension were loaded in both chambers. Cells were viewed under a microscope at 100x 
magnification, and cells contained within 1 mm2 areas on both side were counted [37]. The 
total cell number was calculated as follows: 
 
Cells/ml  =  Total cells counted in 2 mm2 x 104 / Number of mm2 
Total number of cell  = Cells/ml x Total volume of cell suspension (10 ml) 
 
To determine the effect of 8, 9-epoxy-EPA on MCF-7 cell viability, cells were counted using 
a Hematocytometer. Cells were harvested, centrifuged at 1250 rpm (Eppendorf Centrifuge 
5417 R, Crown Scientific) at 4°C for 5-10 minutes and resuspended in 1 ml DMEM. To 
determine the number of viable cells the cell suspension was diluted 1:1 with Trypan blue 
stain. The non-viable cells appeared as blue, while the viable cells were clear. The number of 
viable cells in 2 mm2 was counted and the number of viable cells was calculated as follows:  
 
Cells/ mm2 =  Viable cells counted in 2 mm2 / Number of mm2 
Cells/ml =  Cells/mm2 x 104 / Dilution (1/2) 
Total cells = Cells/ml x Total volume of cell suspension (1 ml) 
 
2.5 Seeding of MCF-7 cells 
Cells were seeded in 24-well plates at cell density 1x105 or 2x105 cells/well/ml. After 24 
hours in media containing 10% FBS the media was changed to media containing the 
appropriate FBS concentration, which was 2% FBS or 0% FBS. Cells grown in media 
containing 2% or 0% FBS was given media containing the test compounds after 24 hours. 





2.6 Harvesting MCF-7cells. 
Media was removed, and cells were washed with 1 ml/well PBS. 0.2 ml/well trypsin was 
added, and cells were incubated at 37°C for 10 minutes. The 24-well plates were tapped 
carefully to detach cells from the plate. Cells were harvested using 2x 0.5 ml DMEM, and 
transferred to 1.5 ml eppendorf tubes for counting, fixing or freezing.  
 
2.7 MTT-assay 
MTT-assay was used to determine the effect of seeding density and serum on MCF-7 cell 
growth. MTT-assay is a rapid and convenient method for determining viable cell number. 
Cells seeded in 24-well plates were added 125 µl/well of 2.5 mg/ml MTT-stock (thiazolyl 
blue tetrazolium bromide), and incubated at 37 °C for 2 hours. Active mitochondrial reductase 
enzymes in viable cells reduce the tetrazolium salt of the dye solution into a formazan 
product. Media with MTT-solution were removed and 0.2 ml/well of DMSO were added to 
dissolve the blue crystals that were formed. Plates were protected from light, and shaken for 
30 minutes on a rotating platform. 100 µl of sample were transferred into 96-well plate, and 
the plate was measured at 540 nm to detect the formazan product using a Victor3 Wallac 1420 
multilabel counter (Perkin, Elmer). The absorbance reading at 540 nm is directly proportional 
to the number of viable cells [38]. 
 
2.8 Flow cytometry 
Flow cytometry is a method that can be used to quantify cells present in the different phases 
of the cell cycle. After harvesting cells were centrifuged at 1250 rpm (Eppendorf Centrifuge 
5417 R, Crown Scientific) at 4°C for 10 minutes, and washed with 0.5 ml ice-cold PBS and 
resuspended. Cells were then centrifuged at 1250 rpm (Eppendorf Centrifuge 5417 R, Crown 
Scientific) at 4°C for 10 minutes. The supernatant was removed, the eppendorf tube was 
“flipped”, and the cell pellet was washed with 0.5 ml PBS. The eppendorf tube was 
centrifuged at 1250 rpm (Eppendorf Centrifuge 5417 R, Crown Scientific) at 4°C for 10 
minutes, and the supernatant was removed. 0.5 ml of pre-cooled 80% ethanol was added, and 
the cells were resuspended. Cells were stored in the -20 °C freezer for at least one hour, and 
then centrifuged at 1250 rpm (Eppendorf Centrifuge 5417 R, Crown Scientific) at 4°C for 15 
minutes, and the ethanol was removed. 0.5 ml of incubation buffer was added, and cells were 
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resuspended. 12.5 µl of propidium iodide was added, and eppendorf tubes were vortexed. 
After 1 hour on ice cell samples were analyzed using a Coulter flow cytometer (Beckman). 
 
2.9 Quantification of total lysate protein   
Cell samples for western blotting was added the appropriate volume of lysis buffer, and the 
lysate protein content was determined by the Bicinchoninic-assay (BCA-assay). The 
absorbance at 540 nm was measured using a Victor3 Wallac multilabel counter (Perkin 
Elmer). A BCA standard curve was used to determine the total lysate protein content in cell 
samples (see Appendix, 6.1 Procedure for BCA-assay).  
 
2.10 Western blotting 
The expression of different cell cycle regulatory proteins in differently treated cells was 
measured by western blotting.  
 
Protein lysate samples stored in the -80°C freezer were thawed. The appropriate amount, 
determined by quantification of total protein lysate (see Appendix, 6.1 Procedure for BCA-
assay), was transferred to an eppendorf tube. Deionized water was added to adjust volumes. 
The samples were diluted 1:1 with sample buffer, and boiled at 100°C for 5 minutes, and then 
centrifuged for 1-2 minutes.  The samples and the marker (Prestained protein molecular 
weight marker) were applied to the gel (see Appendix, 6.2 Procedure for western blotting). 
Gel electrophoresis, blotting and development of the blot were performed as described in 
Appendix, 6.2 Procedure for western blotting. The primary and secondary antibodies (Santa 
Cruz biotechnology, Santa Cruz, CA, USA) used in development are listed in table 2.22. Blots 












Primary antibody  Dilution of  
primary antibody 




Anti-mouse 1:15 000 
CDK 4 1:500 Anti-mouse 1:15 000 
CDK 6 1:1000 Anti-rabbit 1:15 000 
Cyclin A 1:1000 Anti-rabbit 1:15 000 
Cyclin B1 1:1000 Anti-mouse 1:15 000 
Cyclin D1 1:500 
1:200 
1:150 
Anti-mouse 1:15 000 
Cyclin E 1:500 Anti-mouse 1:15 000 
 
2.11 Statistical analysis 


















3.1 Effect of seeding density and serum on MCF-7 cell growth 
The effect of seeding density and serum (FBS) on MCF-7 cell growth was determined in 
preliminary experiments.  Cells were seeded in 24-well plates, and were treated with 8, 9-
epoxy-eicosapentaenoic acid (8, 9-epoxy-EPA; 10 µM). From previous experience in this 
laboratory the seeding density was tested in the range 2-4.8x105cells/ml. The lowest possible 
FBS concentration was considered desirable, because of its potent stimulatory effect on cell 
growth. The FBS range from 0% to 10% was tested. The effects of seeding density and serum 
were assessed by MTT-assay.   
 
In figure 3.1 MCF-7 cells were seeded at 2x105 cells/well, 4x105 cells/well and 4.8x105 
cells/well in media containing 0%, 5% and 10% FCS. Confluences at the seeding density of 
2x105 cells/well in media containing 0%, 5% and 10% FBS were 20-30%, 40-50% and 50-
60% at 24 hr, respectively. Cells that were seeded at 4x105 /well and 4.8x105 /well were fully 
confluent at 24 hr, therefore concentrations lower than 2x105 cells/ml would be most suitable. 
Cell growth was stimulated at concentrations higher than 0% of FBS, as expected (figure 3.1). 
As a result of these experiments 1x105 cells/ml were used in subsequent experiments. Thus, 
cells were seeded at 1x105 and 2x105 cells/well in media containing 0%, 2% and 5% FBS, and 
MTT-assay was performed at 0, 24, 48 and 72 hr. In serum-free media cell growth stopped 
after 24 hours (figure 3.2). At a seeding density of 1x105 cells/ml an increase of 67.2% (2% 
FBS) and 61.5% (5% FBS) was noted at 24 hr compared to 0 hr.  At 48 hr the increases were 
135.9% (2% FBS) and 142.8 % (5% FBS) compared control, and at 72 hr were 220.9% (2% 
FBS) and 214.0 % (5% FBS), respectively. Cells seeded at 2x105 cells/well were increased by 
34.0% (2% FBS) and 37.5 (5% FBS) at 24 hr compared control at 0 hr. At 48 hr increases of 
54.3% (2% FBS) and 57.8% (5% FBS) compared control, and at 72 hr to102.9% (2% FCS) 
and 74.9 % (5% FCS) compared control. Minimal differences in cell growth were observed 
between cells grown in the presence 2% and 5% FBS at both seeding densities. Two percent 
FBS concentration in media was selected for the 8, 9-epoxy-EPA experiments in MCF-cells 
(density 1x105 cells/ml). 
 
 
Figure 3.1: Effect of seeding density and serum on MCF-7 cell growth at 24 hr in 24-wellplates. Cells were 
seeded at 2x105 cells/well in media containing 0% (A), 5% (B) and 10% FBS (C) or at 4x105 cells/well in media 
containing 0% (D), 5% (E) and 10% FBS (F). Further cells were seeded at 4.8x105 cells/well in media containing 
0% (G), 5% (H) and 10% FBS (I). The confluence at seeding density 2x10^5 cells/well in media containing 0% 




Figure 3.2: Effect of seeding density and serum on MCF-7 cell growth measured by MTT-assay. MCF-7 
cells were seeded in 24-well plates at densities of 1x105 (1) and 2x105 (2) cells/well and in media containing 0%, 
2% and 5% FBS. MTT assays were conducted at 0, 24, 48 and 72 hr. Data are expressed as means ± SE from 
two independent experiments. 1: At 24 hr the mean percentage compared to measurement at 0 hr are increased 
31.8% (0% FBS), 67.2% (2% FBS) and 61.5% (5% FBS). At 48 hr the mean percentage compared to 0 hr is 
increased 5.0% (0% FBS), 135.9% (2% FBS) and 142.8 % (5% FBS). At 72 hr the mean percentage compared to 
0 hr are increased 9.0% (0% FBS), 220.9% (2% FBS) and 214.0% (5% FBS).  
2: At 24 hr the mean percentage compared 0 hr is increased 23.5% (0% FBS), 34.0% (2% FBS) and 37.5% (5% 
FBS). At 48 hr the mean percentage compared to 0 hr are increased 22.3% (0% FBS), 54.3% (2% FBS) and 57.8 
% (5% FBS). At 72 hr the mean percentage compared to 0 hr is increased 22.5% (0% FBS), 102.9% (2% FBS) 
and 74.9% (5% FBS).  
 
 
3.2 Effects of 8, 9-epoxy-EPA on cell viability of MCF-7 cells  
The effect of 8, 9-epoxy-EPA on MCF-7 cell viability was assessed after 24 hours of 
treatment. The number of viable cells was manually counted using the Trypan blue assay.   
3.2.1 Effects of 8, 9-epoxy-EPA on viability of MCF-7 cells grown in presence 
of FBS 
MCF-7 cells were seeded at 1x105cells/well in 24-well plates and exposed to 8, 9-epoxy-EPA 




From figure 3.3 the confluences for cells treated with 8,9-epoxy-EPA and 8, 9-epoxy-
EPA+DCU are significantly lower than for control cells (DMSO) and DCU-treated cells after 
24 hr. 8, 9-Epoxy-EPA (10 µM) decreased viable cells by 21.5% ± 6.3%  compared to control 
(figure 3.4 ; p=0.03). The combination of 8, 9-epoxy-EPA (10µM) and DCU (10µM) 




Figure 3.3: Growth inhibition of MCF-7 cells by 8, 9-epoxy-EPA. 1x105cells/well were seeded in 24-well 
plates and cultured in media containing 2% FBS for 24 hr. Treatment consist of DMSO (A, control), 8, 9-epoxy-
EPA (B), DCU (C) and 8, 9-epoxy-EPA + DCU (D). The confluences at 24 hr are approximately 80% (A, 

































Figure 3.4: Effect of 8, 9-epoxy-EPA on the growth of MCF-7 cells. 1x10^5 cells/well were seeded in 24-well 
plates, to which DMSO (control), 8, 9-epoxy-EPA or DCU were added in media containing 2% FCS.  Viable 
cell numbers were counted by Trypan blue assay at 24 hr. Data are expressed as means ± SE from three 
independent experiments. *Viable cell number decreased 21.2% ± 6.3 % for 8, 9-epoxy-EPA-treated cells 
compared to control cells (DMSO) (p = 0.03).**Viable cell number decreased 26.2% ± 8.9% for cells treated 
with 8, 9-epoxy-EPA+DCU compared to control cells (DMSO) ( p = 0.03). 
 
3.2.2 Effects of 8, 9-epoxy-EPA on viability of MCF-7 cells cultured in the 
absence of FBS 
To determine whether  the effect of 8, 9-epoxy-EPA on MCF-7 cells was dependent on the 
presence of FBS, an experiment with serum-free media was carried out. MCF-7 cells were 
seeded at 2x105 cells/well in 24-well plates to which 8, 9-epoxy-EPA (10 µM), DCU (10 µM) 
or both 8, 9-epoxy-EPA (10 µM) + DCU (10µM) were added. Viable cells were counted by 
Trypan blue assay. 8, 9-epoxy-EPA-treatment did not alter viable cell number after 24 hours 
compared to control cells or DCU-treated cells (figure 3.5). Thus, it emerges that the effect of 
8, 9-epoxy-EPA is dependent on the presence of serum. However, the combined effect of 8, 9-
epoxy-EPA+DCU showed a trend toward a decrease. It is feasible that serum may have 




Figure 3.5: Effect of 8, 9-epoxy-EPA on the viability of MCF-7 cells. 2x105 cells/well were seeded in 24-well 
plates, to which DMSO (control), 8, 9-epoxy-EPA, DCU or both were added in serum-free media. Viable cell 
numbers were counted by Trypan blue assay at 24 hr. Data are expressed as means ± SE from three independent 
experiments.  The number of viable cells did not decrease significantly for 8, 9-epoxy-EPA-treated cells 
compared to control cells (DMSO) and DCU-treated cells. 
 
 
3.3. Effects of 8, 9-epoxy-EPA on cell cycle progression in MCF-7 cells   
To investigate the effects of 8, 9-epoxy-EPA on MCF-7 cell growth, we used flow cytometry 
and monitored cell cycle progression. MCF-cells were treated with 8, 9-epoxy-EPA for 6, 16 
and 24 hours, and DNA was stained with propidium iodide.  The cells were analyzed by flow 
cytometry for quantification of cells present in G0/G1, S and G2/M phase. 
 
MCF-7 cells treated for 6 hours with 8, 9-epoxy-EPA, DCU and a combination of 8, 9–epoxy-
EPA + DCU in presence and in absence of FBS did not show a significant change in the cell 
cycle progression compared with control (table 3.1a). The exception was the significant 
increase in the % of cells in G2/M-phase for cells grown in the absence of FBS and treated 






After 16 hours of treatment with 8, 9-epoxy-EPA in presence of FBS a significant 5.7%±1.2% 
(p=0.01) increase in % of cells in G0/G1 phase compared to control was seen (table 3.1b). 
The combination of 8, 9-epoxy-EPA + DCU increased the % of cells in G0/G1-phase by 8.3% 
± 1.5% (p=0.002) compared to control, and cells treated with DCU increased by 8.7% ± 1.6% 
(p=0.002) compared to control. Cells grown in the absence of FBS and treated with 8, 9-
epoxy-EPA + DCU showed a significant 27.4% ± 0.6% (p=0.01) decrease in % of cells in S-
phase compared to cells treated with DCU (figure 3.1b). 
 
24 hours of 8, 9-Epoxy-EPA-treatment in the presence of FBS increased the proportion of 
MCF-7 cells in G0/G1-phase by 3.8% ± 0.8% over control (p=0.002). Whereas 8, 9-epoxy-
EPA+DCU increased the cells in G0/G1-phase by 6.0% ± 0.5 over control (p<0.0001) and 
3.5% ± 0.7% over cells treated with DCU (p=0.003). A corresponding decrease in the 
proportion of cells in G2/M-phase for 8, 9-epoxy-EPA and 8, 9-epoxy-EPA+DCU was 
observed, as shown in table 3.1c. Figure 3.1c also shows that, in cells treated in the absence of 
FBS, the cell cycle progression did not change.  
 
Table 3.1a: Effects of 8, 9-epoxy-EPA on cell cycle progression in MCF-7 cells. Flow cytometry analysis of 
MCF-7 cells treated with DMSO (control), 8, 9-epoxy-EPA, 8, 9-epoxy-EPA + DCU and DCU for 6 hours for 
G0/G1, S and G2/M phase quantification. Data are expressed as mean percentage of total cells ± SE from three 
independent experiments. 
6 hours treatment 
 % of cells in G0/G1-phase % of cells in S-phase % of cells in G2/M-phase 
 2 % FCS 0 % FCS 2 % FCS 0 % FCS 2 % FCS 0 % FCS 
Control 66.7 ± 0.5 89.0 ± 0.4 18.8 ± 0.7 6.1 ±0.4 13.5 ± 0.7 4.8 ± 0.9 
8, 9-epoxy-EPA  66.0 ± 0.4 86.7 ± 0.9 19.6 ± 1.1 6.1 ± 0.1 12.7 ± 1.1 6.1 ± 0.4 
8, 9-epoxy-EPA + DCU 65.1 ± 1.1 85.8 ± 0.8 19.4 ± 0.4 6.4 ± 0.8 13.5 ± 1.0 6.8 ± 0.2 * 
DCU 66.3 ± 0.6 85.3 ± 1.4 19.0 ± 0.3 7.1 ± 1.3 13.2 ±0.7 6.4 ± 0.1 
*Significant 41.9% ± 1.1% (p=0.02) increase of cells treated with 8, 9-epoxy-EPA +DCU in % of cells in G2/M-






Table 3.1b: Effects of 8, 9-epoxy-EPA on cell cycle progression in MCF-7 cells treated for 16 hours. Flow  
cytometry analysis of MCF-7 cells treated with DMSO (control), 8, 9-epoxy-EPA, 8, 9-epoxy-EPA + DCU and 
DCU for 16 hr for G0/G1, S and G2/M phase quantification. Data are expressed as mean percentage of total cells 
± SE from three independent experiments. 
16 hours treatment 
 % of cells in G0/G1-phase % of cells in S-phase % of cells in G2/M-phase 
 2 % FCS 0 % FCS 2 % FCS 0 % FCS 2 % FCS 0 % FCS 
Control 61.5 ± 0.6 85.0 ± 1.7 23.2 ± 1.7 7.0 ±0.6 13.2 ± 1.2 6.8 ± 1.1 
8, 9-epoxy-EPA  65.0 ± 0.6 * 84.5 ± 1.1 19.7 ± 1.4 6.8 ± 0.7 12.4 ± 1.0 7.5 ± 0.4 
8, 9-epoxy-EPA + DCU 66.7 ± 0.9 * 85.4 ± 1.0 20.1 ± 1.4 6.0 ± 0.3 # 12.0 ± 1.4  7.2 ± 0.1 
DCU 66.8 ± 1.0 * 82.4 ± 0.1 19.2 ± 1.1 8.3 ± 0.3 12.0 ± 1.0 8.0 ±0.2 
*Significant increase in % of cells in G1 phase compared to control; 5.7% ± 1.2% (8, 9-epoxy-EPA, p=0.01), 
8.3% ± 1.5% (8, 9-epoxy-EPA + DCU, p=0.002), 8.7% ± 1.6% (DCU, p=0.002). 
#Significant 27.4% ± 0.6% (p=0.01) decrease of cells treated with 8, 9-epoxy-EPA +DCU in % of cells in S-
phase compared to cells treated with DCU. 
 
Table 3.1c: Effects of 8, 9-epoxy-EPA on cell cycle progression in MCF-7 cells treated for 24 hours. Flow 
cytometry analysis of MCF-7 cells treated with DMSO (control), 8, 9-epoxy-EPA, 8, 9-epoxy-EPA + DCU and 
DCU for 24 hr for G0/G1, S and G2/M phase quantification. Data are expressed as mean percentage of total cells 
± SE from three independent experiments. 
24 hours treatment  
 % of cells in G0/G1-phase % of cells in S-phase % of cells in G2/M-phase 
 2 % FCS 0 % FCS 2 % FCS 0 % FCS 2 % FCS 0 % FCS 
Control 61.7±0.2 83.2 ± 1.7 17.3±1.5 7.4 ± 0.7 17.0±1.1 7.5 ± 0.7 
8, 9-epoxy-EPA  64.1±0.6 * 84.5 ± 1.6 18.9±0.8 7.3 ± 0.6 13.2±0.6 # 6.1 ± 0.6 
8, 9-epoxy-EPA + DCU 65.4±0.3 * 84.6 ± 0.8 18.1±0.8 7.2 ± 0.5 12.7±0.5 # 7.0 ± 1.0 
DCU 63.2±0.4* 83.2 ± 1.4 17.9±0.5 7.3 ± 0.9 14.7±0.5 # 8.0 ± 0.5 
*Significant increase in % of cells in G0/G1-phase compared to control; 3.9% ± 0.8% (8, 9-epoxy-EPA, 
p=0.002), 6.0% ± 0.5% (8, 9-epoxy-EPA+DCU, p<0.0001), 2.4% ± 0.6% (DCU, p=0.04).  Cells treated with 8, 
9-epoxy-EPA was 3.5% ± 0.7% (p=0.003) increased in % of cells in G0/G1-phase compared to DCU. 
#Significant decrease in % of cells in G2/M-phase compared to control: 22.6% ± 1.7% (8, 9-epoxy-EPA, 
p=0.0001), 25.6% ± 1.6% (8, 9-epoxy-EPA+DCU, p=0.0004), 13.8% ± 1.6% (DCU, p=0.03).  Cells treated with 
8, 9-epoxy-EPA were 13.7% ± 0.9% (p=0.047) lower in G2/M-phase compared to DCU. 
 
 
3.4 Cell cycle protein expression in 8, 9-epoxy-EPA-treated MCF-7 cells 
Since clear effects of 8, 9-epoxy-EPA on MCF-7 cell cycle progression were observed, we 
examined changes in expression of different cell-cycle regulatory proteins after treatment with 
8,9-epoxy-EPA and 8, 9-epoxy-EPA + DCU.  
3.4.1 Expression of different proteins in 8, 9-epoxy-EPA-treated MCF-7 cells 
MCF-7 cells were treated with 8, 9-epoxy-EPA for 24 hours and then harvested for western 
blotting. The protein levels of cyclin D1, cyclin E, CDK4, CDK6 and p21 (figure 3.6) were 






             Control                8, 9‐epoxy          Control    8, 9‐epoxy 






Figure 3.6: Effect of 8, 9-epoxy-EPA on cyclin D1, CDK6, cyclin E, CDK4 and p21 protein expression. 
MCF-7 cells were treated with 8, 9-epoxy-EPA and harvested at 24 hr. The relative protein levels of cyclin D1, 
























cyclin D1 cyclin E CDK6 CDK4 p21
 
Figure 3.7: Relative expression of cell cycle regulatory proteins in 8, 9-epoxy-EPA-treated MCF-7 cells at 
24 hr. Data are expressed as means ± SE from three independent experiments.  
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3.4.2 Cyclin D1 expression in 8, 9-epoxy-EPA-treated MCF-7 cells at 6, 16 and 
24 hr 
At our laboratory a decreased expression of cyclin D1 was observed in murine endothelial 
cells after n-3 EPA treatment, and the effect on cyclin D1 was also observed at earlier 
timepoints (at 2, 6 and 16 hr). Since the expression of different cell-cycle regulatory proteins 
at 24 hr did not account for the effects of 8, 9-epoxy-EPA observed on the cell cycle, we 
examined the expression of cyclin D1 at 6, 16 and 24 hr (the 24 hr timepoint is shown in 
figure 3.8). In this experiment the combined effect of epoxide + DCU was assessed. However, 
expression of cyclin D1 was unaltered after either 8, 9-epoxy-EPA or combined 8, 9-epoxy-
EPA+DCU treatment for 6, 16 and 24 hr (figure 3.9 A-C). Thus, despite the growth inhibition 
effects of the epoxide and the relative accumulation of cells in G0/G1 phase, no clear 
evidence of cyclin D1 dysregulation was observed. It is possible that cyclin D1 dysregulation 
occurred at a very early timepoint after epoxide addition or that another regulatory cyclin may 
have been affected by epoxy-EPA. 
 
 
             Control             8, 9‐epoxy                      Control     8, 9‐epoxy       DCU 






Figure 3.8: Effect of 8, 9-epoxy-EPA on cyclin D1expression. MCF-7 cells were treated with 8, 9-epoxy-EPA, 
DCU and the combination of 8, 9-epoxy-EPA+DCU and harvested at 24 hr. The relative protein level of cyclin 







Figure 3.9: Expression of cyclinD1/actin (A and B) and cyclin D1 expression/actin % of control (C) in 
MCF-7 cells treated with 8, 9-epoxy-EPA and 8, 9-epoxy-EPA+DCU for 6 hr (A), 16 hr (B) and 24 hr (C). 





































Several studies have been undertaken in vivo and in vitro that have suggested that n-3 PUFAs 
inhibit the growth and spread of  cancer cells, including breast cancer cells [16-23]. However, 
the mechanism is not fully understood. Experiments have shown that the n-3 PUFA EPA 
inhibits growth of MCF-7 breast cancer cells [16, 21, 23]. Metabolism of EPA by the CYP-
450 system results in five regioisomeric epoxyeicosatetraenoic acids (5,6-, 8,9-, 11,12-, 
14,15-, and 17,18-epoxy-EPAs) [9]. Previous studies have shown that murine endothelial cells 
are stopped from proliferating by these epoxides (unpublished data). The present project 
tested whether 8, 9-epoxy-EPA might contribute to growth inhibition of EPA in human breast 
cancer cells. Positive findings would provide mechanistic insight into the anticancer 
properties of n-3 PUFA.  
 
There were two major approaches in this study. The first was to test 8, 9-epoxy-EPA alone 
and in combination with DCU on MCF-7 cell proliferation. The second was to test the 
influence of serum on the effect of 8, 9-epoxy-EPA on MCF-7 cells. The reason for these 
approaches was to directly evaluate the potential of the epoxides to inhibit cancer growth and 
to explore some of their performance characteristics. Use of the epoxide hydrolase inhibitor 
DCU would provide information on the role of epoxide hydrolase in the duration of action, 
and serum provides a direct growth stimulus.  
 
4.1 Effects of 8, 9-epoxy-EPA on cell viability 
We first tested the effect of 8, 9-epoxy-EPA on cell viability. Our experiments showed a 
decrease in cell viability of MCF-7 cells treated with 8, 9-epoxy-EPA and with the 
combination of 8, 9-epoxy-EPA + DCU, compared to control. Chamras et al [21] tested 
among other things the influence of EPA and DHA on the proliferation of MCF-7 cells. They 
found that both EPA and DHA inhibited MCF-7 cell growth, which are in agreement with our 
findings by using a combination of cell count by Trypan blue assay and microscopy. Because 
the role of biotransformation was not evaluated in that study it is possible that eicosanoid 
metabolites may be important. The present findings indicate that 8, 9-epoxy-EPA may 
contribute to the beneficial effects of the n-3 polyunsaturated against breast cancer cells. This 
is in contrast with the growth stimulatory effects of the n-6 PUFA epoxide, termed EETs [36].  
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We also tested the effect of 8, 9-epoxy-EPA in combination with DCU. DCU is an epoxide 
hydrolase inhibitor, which decrease the conversion of EETs to the corresponding 
dihydroxyeicosatrienoic acids (DHETs) by epoxide hydrolase (EH). By adding an epoxide 
hydrolase inhibitor the enzymatic degradation of EET was inhibited, and the amount of EETs 
in cells enhanced [11].   
 
Thus, some cells were treated with a combination of 8, 9-epoxy-EPA and DCU and control 
cells received DCU. Cells treated with the combination of 8, 9-epoxy-EPA+DCU showed 
slightly decreased viability 26.3% ± 8.9%,  while cells treated with only 8, 9-epoxy-EPA 
showed a 21.5% ± 6.3%  decrease compared to control, but these differences were not 
significant. However, it is noteworthy that MCF-7 cells, like murine endothelial cells, are 
subject to decreased viability in the presence of the parent n-3 PUFA EPA and its 8, 9-
epoxide.    
 
MCF-7 cells are estrogen responsive and contain the estrogen receptor [35]. Estrogen plays an 
important role in regulating proliferation and protein synthesis in MCF-7 cells. Serum is 
known to contain both estrogenic hormones and growth factors that will influence the growth 
of MCF-7 cells. The concentration of serum in the growing media is extremely important for 
the proliferation of MCF-7 cells. Treatment with 8, 9-epoxy-EPA and the combination of 8, 9-
epoxy-EPA + DCU on cells grown in serum-free media did not alter cell viability. This was 
confirmed by microscopy, which showed that confluence was not altered. This indicates that 
the effect of 8, 9-epoxy-EPA on MCF-7 cells is dependent on the presence of serum and is 
important because it implies that growth inhibition by epoxides requires an additional 
proliferative stimulus. Thus, epoxides were ineffective in growth retarded cells but effective 
during breast cancer cell proliferation.    
 
In this study media containing phenol red was used. Phenol red is a pH-indicator used in 
media, which have a structural resemblance to some nonsteriodal estrogens and therefore have 
estrogenic activity which can stimulate the growth of MCF-7 cells [39]. Since the mechanism 
of the growth inhibition effect of 8, 9-epoxy-EPA on MCF-7 is not known, and this study 
focused on cell cycle related mechanism media containing phenol red was used. If a 
mechanism involving estrogen activity or receptors was studied phenol-free media and 
charcoal stripped serum must have been used.  
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4.2 Effects of 8, 9 –epoxy-EPA on cell cycle progression in MCF-7 cells. 
The effect of 8, 9-epoxy-EPA on MCF-7 cell viability was further investigated by monitoring 
cell cycle progression using flow cytometry. Cells were analyzed by flow cytometry for 
quantification of cells present in G0/G1, S and G2/M phase at 6, 16 and 24 hr. 
 
Cells treated for 6 hours with 8, 9-epoxy-EPA, DCU and a combination of 8, 9–epoxy-
EPA+DCU in the presence of FBS did not show a significant change in the cell cycle 
progression compared with control. Cells treated in the absence of FBS showed a slight 
decrease in the proportion of cells in G0/G1-phase, with a corresponding slight increase in 
G2/M-phase for cells treated with 8, 9-epoxy-EPA, DCU and the combination of 8, 9-epoxy-
EPA+ DCU compared to control. Only the increase in % of cells in G2/M-phase for cells 
treated with the combination of 8, 9-epoxy-EPA+DCU was found to be significant compared 
to control.  
 
The cell cycle analysis also showed that there was an increase of cells in G0/G1 phase for 
cells grown in the absence of FBS compared to cells grown in presence of FBS. This probably 
means that the cells are prevented from entering G1 phase, and the cell cycle progression is 
different compared to cells grown in presence of FBS. The alteration of the cell cycle 
progression for cells grown in the absence of FBS shows again the influence of FBS on MCF-
7 cell growth. To further evaluate these effects longer term treatments were performed.  
 
After 16 hours of treatment with 8, 9-epoxy-EPA, DCU and the combination of 8, 9-epoxy-
EPA + DCU in the presence of FBS the proportion of cells in G0/G1-phase were significantly 
increased compared to control. However these effects were relatively small. This indicates 
that both treatment with 8, 9-epoxy-EPA and DCU alone has an effect on cell cycle 
progression at 16 hours. There was also a corresponding slight decrease in the proportion of 
cells in S-phase, but the decrease was not significant.  
 
However, 24 hours of 8, 9-epoxy-EPA-treatment in the presence of FBS showed an 
accumulation of MCF-7 cells in G0/G1-phase compared to control. A corresponding decrease 
in the proportion of cells in G2/M-phase for 8, 9-epoxy-EPA and 8, 9-epoxy-EPA+DCU was 
also observed. A study which examined the effect of DHA on cell growth, cell cycle 
progression and expression of cell cycle regulatory proteins in KPL-1 cells, which also is a 
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human breast cancer cell line that is estrogen receptor positive, also found the same inhibitory 
effect on breast cancer cell growth, and an arrest of cells in G1-phase at 24 hours [22]. At 6 
hours treatment they did not see any change in cell cycle progression, which is also consistent 
with our results. 
 
The cell cycle analysis indicated that MCF-7 cells treated with 8, 9-epoxy-EPA for 16 and 24 
hours were arrested in G0/G1 phase, and did not progress through the cell cycle at the same 
rate as control cells. It also showed that DCU alone increased the number of cells in G0/G1-
phase compared to control, and in combination with 8, 9-epoxy-EPA the increase of the 
proportion of cells in G0/G1-phase was not significant higher than the treatment with 8, 9-
epoxy-EPA alone. The adding of DCU does not seem to enhance the effect of the 8, 9-epoxy-
treatment on cell cycle progression significantly, but may also contribute to growth inhibition 
by stabilizing endogenous epoxide in cells. The 24 hours treatment of MCF-7 cells in the 
absence of FBS did not alter the cell cycle progression. This is consistent with outcomes of 
experiments that tested the effect of 8, 9-epoxy-EPA on MCF-7 cell viability: the effect of 8, 
9-epoxy-EPA is dependent on the presence of FBS. 
 
4.3 Cell cycle protein expression in 8, 9-epoxy-EPA-treated MCF-7 cells. 
The effects on cell viability and cell cycle progression were further investigated by examining 
changes in the expression of cell cycle regulatory proteins. Cell cycle progression is regulated 
by the cyclin system. Cyclin D1 is the master regulator of this process and is switched on in 
cells after a proliferative stimulus, e.g. in MCF-7 cells by exposure to estrogen and growth 
factors present in serum. Cyclin D1 acts together with cyclin-dependent kinases (CDKs), 
which phosphorylate downstream proteins to activate gene expression in the nucleus. CDK-
inhibitors (CDKIs), such as p21 and p27, interact with the cyclin-CDK complex to regulate 
target protein phosphorylation. In this study we tested whether the small changes in cell cycle 
distribution might occur along with altered expression of cyclins, CDKs and CDKIs.  
 
We found the expression of cyclin D1, cyclin E, CDK4, CDK6 and p21 to be unchanged in 8, 
9-epoxy-EPA-treated MCF-7 cells. Inclusion of DCU did not alter this finding. n-3 Epoxy 
EPA has been found to strikingly decrease the expression of cyclin D1 protein and mRNA 
expression in murine endothelial cells. A decrease in CDK4, which forms a functional 
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complex with cyclin D1, was also noted but other cyclins, and CDKIs were unaffected. The 
present findings that cyclin D1 expression was unchanged by epoxide treatment in the 
presence or absence of the epoxide hydrolase inhibitor DCU suggests that the cyclin is 
regulated differently in MCF-7 cells. At this point the signaling mechanisms in cells involving 
n-3 epoxy EPA are unclear. After these have been clarified it may be possible to account for 
these cell-type-specific effects. Another potential mechanism is that epoxy EPA may exert an 
apoptotic effect in MCF-7 cells. That is, they may stimulate programmed cell death rather 
than decreasing cell proliferation. This could account for the present finding that cell viability 
and cell cycle distribution are impaired by the epoxide in the absence of cyclin D1 effect.    
 
In summary we found have that 8, 9-epoxy-EPA inhibited the growth of MCF-7 cells, which 
is in agreement with other studies that have shown similar inhibitory effects of EPA on MCF-
7 cell growth [16, 21, 23]. The effect of 8, 9-epoxy-EPA on MCF-7 cell viability has been 
shown to be dependent on the presence of FBS, which is also required for the effect of 
linoleic acid on MCF-7 cell growth [40]. We also studied the mechanism in relation to cell 
cycle by using flow cytometry and western analysis. The results from the cell cycle analysis 
showed a significant increase in the proportion of cells in the G0/G1-phase for cells treated 
for 16 hours with 8, 9-epoxy-EPA, DCU and 8, 9-epoxy-EPA+DCU compared to control. 
After 24 hours there was an accumulation of treated cells in the G0/G1-phase with a 
corresponding decrease in G2/M-phase compared to control. Treatment in the absence of FBS 
showed no alteration in the progression of the cell cycle. The expression of cell cycle 
regulatory proteins did not show any change between treated cells and control. Thus, the 
growth inhibition effect may be due to increased cell apoptosis as an alternative to decreased 









































































































































6.1 Procedure for BCA-assay 
Total protein lysate preparation: 
• Prepare part A (table 6.1) and lysis buffer (table 6.2). 
• Add 2x 0.5 ml of ice-cold PBS to cell samples, stored in -80 °C freezer, to transfer 
cells to an eppendorf tube. 
• Centrifuge cell samples at 10 000 g at 4 °C for 5 minutes. 
• Remove supernatant. 
• Add 20 µl of lysis buffer per cell sample harvested from one well in a 24-well plate, 
and vortex samples.  
• Leave samples on ice for 40 min, and centrifuge at 10 000 g at 4 °C for 10 minutes. 
• Transfer 4 µl of the supernatant to a BCA eppendorf tube, and store at -80°C. 
 
Table 6.1 
Part A in lysis buffer, 10 ml 
1x PBS 6.49 ml  
1% Igepal 1 ml  
0.5% Sodium deoxycholate  2.5 ml  
0.1% SDS 0.05 ml  
 
Table 6.2 
Lysis buffer (part A + phosphatase inhibitors), 5 ml 
Part  A 4992.5 ml 
0.1 mM PMSF  2.5 ml  
5 ug/ml Aprotinin 2.5 ml  
5 ug/ml Leupeptin 2.5 ml  
 
 
Quantification of protein:  
•  Dilute 4 µl of protein samples from total protein lysate with 66 µl of deionized water 
(dilution factor 17.5). 
54 
 
• Dilute 400 µl lysis buffer with 6600 µl deionized water (dilution factor 17.5). 
• Prepare BSA (bovine serum albumin) standards as per table 6.3 using the BSA stock 
2mg/ml and diluted lysis buffer.  
 
Table 6.3: BSA-standards 
Tube Diluted lysis buffer,  
(µl) 




A 0 300 of 1x stock 2000 
B 125 375 of 1x stock 1500 
C 325 325 of 1x stock 1000 
D 175 175 of B 750 
E 325 325 of C 500 
F 325 325 of E 250 
G 325 325 of F 125 
H 120 180 of G 75 
I 300 200 of G 50 
J 400 100 of G 25 
K 150 150 of J 12.5 
L 400 0 0 (= blank) 
 
• Prepare working solution by using BCA Protein Assay Reagent kit (Pierce), and mix 
40 ml of reagent A and  0.8 ml of reagent B (50A : 1B). 
• Add 25 µl of each BSA standard and test sample in duplicate into a 96 well plate. 
• Add 200 µl of working solution into each well using a multi channel-pipette. 
• Put the 96-well plate on an orbital shaker for 30 seconds. 
• Seal the plate with parafilm and incubate at 37 °C for 40 min, and leave the plate to 
cool at room temperature for 30 minutes. 
• Change the lid to avoid water, and read at 540 nm on Victor3 Wallac 1420 multilabel 
counter. 




6.2 Procedure for western blotting 
Gel casting:  
• Put gel casting apparatus together.  
• Prepare 15 ml of 12% separating gel (see Materials and methods, table 2.17) 
•  Apply 5 cm of 12% separating gel into the gel casting apparatus. 
•  Apply 5 drops of water-saturated BeOH evenly across the gel to exclude air during 
polymerization.  
• Leave the gel to set for 30-40 minutes, and wash the gel 5x deionized water to remove 
the BeOH. 
• Prepare 8 ml of 5% stacking gel (see Materials and methods, table 2.18). 
• Apply the stacking gel on top of the separating gel, and insert 1.5 mm 10 well combs.  
• Leave the stacking gel to set for 30 minutes.  
• Carefully remove combs, and wash the gel with deinonized water.  
• Carefully remove water with a syringe. 
 
Gel electrophoresis: 
• Apply 5 µl marker and prepared samples (see Material and methods, 2.10 Western 
blotting) on gel.  
• Prepare 1x electrophoresis buffer (see Material and methods, table 2.10 and 2.11). 
• Add the electrophoresis buffer in the tank, and fill up the wells. 
• Run at 150V using the Power PAC 200.  
• Leave the tank in an icekit. 
• Run the gel until the bromophenol blue completely have reached the end of the gel. 
 
Transfer:  
• Prepare the transfer buffer (see Material and methods, table 2.13) 
• Activate the nitrocellulose membrane by soaking it for 10 minutes in transfer buffer on 








• Prepare the stacks by assembling the components in the following order: 
TOP 
o Clear plastic holder 
o 1 pad 
o 3x Whatman filterpaper 3 mm (8x10 cm)  
o Nitrocellulose membrane 
o Gel 
o 3x Whatman filterpaper 3 mm (8x10 cm)  
o 1 pad 
o Black plastic folder   
BOTTOM 
• Put the stack into the blotting module.  
• Add transfer buffer in to the tank, and put in the blotting module. 
• Set blotting on 100V for 1.5 hour, and fill ice container with ice and replace every 30 
minutes.  
• After the transfer mark the outline of the gel on the membrane with a pencil to 
orientate.  
• Color the membrane with Ponceau Stain for 10 minutes on an orbital shaker. 
• Quickly wash of Ponceau Stain with deinonized water, and scan the membrane on a 
Biorad GS-800 Calibrated Densitometer. 
 
Development of the blot: 
• Incubate the blot in a tray with 10 ml of 5% blocking milk solution (see Materials and 
methods, table 2.16) for 1 hour on the shaker.  
• Pour out the blocking solution, and incubate the blot in a tray with 10 ml 5% blocking 
milk solution and the appropriate primary antibody overnight at 4 °C on an orbital 
shaker. 
• Wash the blot 5x 5 minutes and 5x 2.5 minutes with 20 ml 1x TBS/Tween (see 
Materials and Methods, table 2.13 and 2.14) on an orbital shaker. 
• Place the blot in a tray with 10 ml of 5% blocking milk solution and the appropriate 
secondary antibody for 1 hour on the shaker.  
57 
 
• Protect the blot from light by using a lid covered in foil. 
 
• Remove the secondary antibody and wash the blot 5x 5 minutes and 5x 2.5 minutes 
with 1x TBS/Tween, and then 2x 5 minutes with TBS (no Tween).  
• Dry the blot between to filter papers. 
• Scan the blot by using Odyssey LI-COR.   
 
